Drug Profile
SUN 131
Alternative Names: SUN-131; SUN-131 TDSLatest Information Update: 29 Sep 2020
Price :
$50
*
At a glance
- Originator Senju Pharmaceutical
- Class Anti-inflammatories; Corticosteroids; Eye disorder therapies
- Mechanism of Action Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Chalazion
Most Recent Events
- 29 Sep 2020 SUN 131 is still in phase III development for Chalazion in USA (Senju Pharmaceutical website, September 2020)
- 17 Aug 2018 Senju completes the SUNRISE phase III trial in Chalazion (In children, In adolescents, In adults, In the elderly) in USA (Transdermal) (NCT03248440)
- 22 Aug 2017 Phase-III clinical trials in Chalazion (In children, In adolescents, In adults, In the elderly) in USA (Transdermal) (NCT03248440)